Скачать или смотреть Which one is better for weight loss, Mounjaro or Ozempic/Wegovy? The SURMOUNT-5 trial headline

Headline: SURMOUNT-5 Trial: Tirzepatide vs. Semaglutide for Weight Loss (Non-Diabetic Adults)

This video summarizes the key findings from the SURMOUNT-5 trial, comparing the effectiveness of tirzepatide (Mounjaro) and semaglutide (Ozempic/Wegovy) for weight loss in adults with obesity who do not have diabetes.

Key Highlights:
Superior Weight Loss: The tirzepatide group achieved a significantly greater average weight loss of 20.2%, compared to 13.7% in the semaglutide group.

Greater Waist Circumference Reduction: Participants on tirzepatide also experienced a larger average reduction in waist circumference (18.4 cm or about 7 inches) compared to the semaglutide group (around 13 cm or about 5 inches).

Conclusion: Tirzepatide (Mounjaro) demonstrated superiority over semaglutide (Ozempic/Wegovy) in reducing both body weight and waist circumference in the studied population.

Safety: Both drugs had acceptable safety profiles, with common gastrointestinal side effects noted.

Important Note: This video is for informational purposes only. Consult with your doctor for personalized health advice and treatment options.

#SURMOUNT5 #Tirzepatide #Semaglutide #WeightLoss #Obesity #ClinicalTrials #Mounjaro #Ozempic #Wegovy #Health